Globus Medical (GMED) Q2 2023 Earnings Call Transcript

Globus Medical (GMED 0.36%)
Q2 2023 Earnings Call
Aug 03, 2023, 4:30 p.m. ET

Contents:

• Prepared Remarks
• Questions and Answers
• Call Participants

Prepared Remarks:

Operator

Welcome to Globus Medical's second quarter 2023 earnings call. [Operator instructions] I will now turn the call over to Brian Kearns, senior vice president of business development and investor relations. Mr. Kearns, please go ahead.

Brian Kearns -- Senior Vice President, Business Development and Investor Relations

Thank you, Didi, and thank you, everyone, for being with us today. Joining today's call from Globus Medical will be Dan Scavilla, president and chief executive officer; and Keith Pfeil, senior vice president and chief financial officer. This review is being made available via webcast, accessible through Investor Relations section of the Globus Medical website at www.globusmedical.com. Before we begin, let me remind you that some of the statements made during this review are or may be considered forward-looking statements.

Our Form 10-K from the 2022 fiscal year and our subsequent filings with the Securities and Exchange Commission identify certain factors that could cause our actual results to differ materially from those projected in any forward-looking statements made today. Our SEC filings, including the 10-K, are available on our website. We do not undertake to update any forward-looking statements as a result of new information or future events or developments. Our discussion today will include certain financial measures that are not calculated in accordance with generally accepted accounting principles or GAAP.

We believe these non-GAAP financial measures provide additional information pertinent to our business performance. These non-GAAP financial measures should not be considered replacements for and should be read together with the most directly comparable GAAP financial measures. Reconciliations to the most directly comparable GAAP measures are available in the schedules accompanying the press release and on the Investor Relations section of the Globus Medical website. With that, I'll now turn the call over to Dan Scavilla, our president and CEO.

Dan Scavilla -- Executive Vice President, Chief Commercial Officer, President of Trauma

Thanks, Brian, and good afternoon, everyone. Globus had a fantastic second quarter, setting a new sales record of $292 million, increasing 11% or $28 million versus Q2 '22. Non-GAAP EPS increased to $0.63, up 12%, and we had a strong free cash flow of $17 million, up 31% versus Q2 '22. Adjusted EBITDA for the quarter was 33%.

Through the first half of '23, Globus has delivered $568 million, an increase of 15% or $74 million over Q2 -- first half of '22. Non-GAAP EPS was $1.15, up 18%, and free cash flow of $54 million was up 44% versus first half '22. These outstanding results are due to the hard work of our dedicated team members across the company and our focus on driving sustainable and profitable growth. Keith will cover these achievements further in his section.

U.S. spine grew 6% in Q2 with notable gains across our product portfolio in biologics, MIS and pedicle screws, and 3D-printed implants. This above-market growth is driven by competitive rep productivity and robotic pull-through. In Q2, we launched three new products, REFLECT, MARVEL, and Ossifuse.

REFLECT is a humanitarian device designed to correct progressive scoliosis in young patients while preserving motion, maintaining stability, and allowing for future modulated growth. Unlike rigid metal rods for fusion, the system uses a flexible, durable cord tensioned on the convex side of the spine to harness the power of patient growth for curve correction. This is a groundbreaking technology that is now available for children in the U.S. REFLECT technology has been used in over 5,000 procedures worldwide and is quickly becoming a very attractive option for parents and children who can now avoid or delay a fusion.

MARVEL growing rods are designed for patients under the age of 10 with early onset scoliosis to obtain and maintain correction while allowing continued growth through minimally invasive distraction. The powerful geared expansion mechanism, access through a small incision provides tactile feedback and a large expansion capability for reliable distraction and minimal soft tissue disruption. REFLECT and MARVEL are part of our strategy to increase innovation and our presence in the pediatric deformity market. Ossifuse, HSA, or high surface area, is composed of 100% allograft bone without an added synthetic carrier.

The demineralized cortical fibers have a unique architecture with high surface area for cellular attachment and multiple handling. Ossifuse is a key component in our growing biologic portfolio. As we move into the second half of 2023 and into 2024, I anticipate a strong cadence of product launches throughout our portfolio. Enabling technology had record sales of $35 million, up 18% versus prior year, driven by robotic and imaging system sales.

Robotic penetration and adoption continue to be strong as we open new accounts and markets worldwide. We continue to make positive inroads with our Excelsius3D imaging system in the U.S., and we're also seeing increased interest in sales and combination deals with both ExcelsiusGPS and E3D as surgeons see the advantage of our seamless integrated offering. Robotic procedures continued to accelerate, growing 41% versus prior year and exceeding 54,000 robotic procedures performed to date, driven by strong procedural adoption of pedicle screw placement, interbody placement, and cranial applications. We're also expanding our investment in enabling technology product development to enhance our ecosystem offering and bring about more functionality in our imaging, navigation, and robotics current and future portfolio.

We're well positioned to partner with our surgeons to bring meaningful innovation into the space. Market interest remains high for our state-of-the-art technologies, and we're entering Q3 with a strong pipeline. Our international spine business, excluding Japan, had a record quarter in Q2, growing 29% on a constant-currency basis compared to prior year. We generated double-digit growth and strong momentum in most markets.

Spain, U.K., Australia, Ireland, India, and Poland all produced growth of 30% or more for the quarter. In addition, Japan had 9% constant-currency growth for Q2. We expect to see gains in Japan throughout the year as we focus on above-market gains to recapture share. Our trauma business delivered its 14th consecutive quarter of sequential growth, generating 63% growth versus Q2 '22 and 12% sequentially.

Trauma performance is driven by salesforce expansion and strong uptake in all product lines with substantial growth throughout our portfolio. We have a robust product pipeline in trauma, and I anticipate several meaningful launches in the second half of '23. To update you on merger status. As mentioned in our last earnings call, both Globus Medical and NuVasive shareholders voted overwhelmingly in support of the merger with over 99% voting for the transaction.

We received a second request from the FTC in May and have been focused on providing the necessary responses while continuing with cross-functional integration planning. We remain fully committed to the merger and our expected Q3 '23 closure date remains unchanged. In summary, we remain focused on the core elements for long-term and sustained growth, innovative new product introductions, robot and imaging system sales, competitive rep recruiting, and merger integration planning. 2023 is all about focus on execution to deliver value to our customers and drive growth.

I know we are well-positioned to achieve our mission of becoming the preeminent musculoskeletal company in the world. I will now turn the call over to Keith.

Keith Pfeil -- Senior Vice President, Chief Financial Officer

Thanks, Dan, and good afternoon, everyone. I am pleased to report that Globus concluded on an exceptionally strong second quarter. Momentum from the first quarter continued into the second quarter, resulting in record revenue and earnings. Revenue in the second quarter of 2023 was $291.6 million, growing 10.6% as reported versus the second quarter of the prior year.

Net income was $57.7 million, resulting in fully diluted earnings per share of $0.57. Non-GAAP net income was $63.6 million, delivering $0.63 of fully diluted non-GAAP earnings per share, resulting in 12.3% growth over the prior-year quarter. Q2 musculoskeletal revenue was $256.9 million, growing 9.7% as reported compared to the prior-year quarter, led primarily by our spine business globally, as well as trauma. Enabling technologies revenue was $34.8 million in the second quarter of 2023, growing 18.2% as reported compared to the prior-year quarter.

Sales growth was led mainly by our E3D imaging system, as well as continued robotic system penetration, primarily in the U.S. Q2 U.S. revenue was $245.5 million, growing 9% versus the prior-year quarter, led by U.S. spine and enabling technologies.

International revenue in the second quarter was $46.1 million, growing 20.2% as reported and 22% on a constant-currency basis and largely due to expanding implant sales. Sales growth was led by our key focus countries, including Spain, the U.K., Australia, India, Poland, and Japan. Regionally, growth was primarily driven in the EMEA region, as well as APAC. Moving further into the P&L.

Second quarter gross profit was 73.8%, compared to 74% in the prior-year quarter. The decline in gross profit rate was driven mainly by the mix of products, namely strong growth in capital sales, as well as a growing mix of international implant sales. Despite the decline in gross profit rate, gross profit dollars grew 10.2% in the quarter, in line with our 10.6% revenue growth. Over the long term, however, our continued expectation is that we are a mid-70s gross profit rate business.

Research and development expenses were $21.3 million or 7.3% of sales in the second quarter of 2023, compared to $17.4 million or 6.6% of sales in the prior-year quarter. The resulting increase in spend was largely focused on spine and enabling technologies and is reflective of headcount growth as we work to develop new technologies to drive continued platforms for future growth. SG&A expenses in the second quarter were $120.1 million or 41.2% of sales, compared to $106.7 million or 40.5% of sales in the second quarter of the prior year. The increased spending is reflective of higher sales compensation costs, driven by volume, competitive rep conversions, and higher G&A costs, driven by increased legal expenses, as well as bad debt expense.

The effective income tax rate for the second quarter was 22.7%, essentially in line with the 22.6% noted in the second quarter of the prior year. Adjusted EBITDA for the quarter was 33%, lower than the 34.9% noted in the -year quarter and is reflective of my earlier comments on sales mix changes, increased R&D investments, as well as increased G&A spending. As we think about Globus over the long term, the leadership has and will continue to strive for mid-30s adjusted EBITDA. Consistent with history during periods of heavier investment, our adjusted EBITDA will track to the lower range of the mid-30s.

The long-term goal remains steadfast. We will focus on continued investment to drive future sales while delivering above-market profitability for our shareholders. Non-GAAP EPS in the second quarter of 2023 was $0.63 or 12.3% higher as compared to the prior-year quarter. Our second quarter 2023 includes an approximate $0.04 tailwind of nonoperating items, mainly driven by higher interest income.

Adjusting for this, our normalized non-GAAP EPS would have been $0.59. Net cash provided by operating activities was $35 million, and free cash flow was $17.2 million. The increase in free cash flow is driven primarily by lower capital expenditures and additional working capital investments, namely inventory, as well as the timing of higher payable spending. At this time, the company is revising its full-year stand-alone 2023 guidance.

We now expect full-year net sales to be $1.125 billion. Our stand-alone fully diluted non-GAAP EPS guidance remains unchanged at $2.30 per fully diluted share. Our Q2 results serve to highlight our collective strength, record revenue, record earnings, and record adjusted EBITDA dollars, all while seeing continued improvement in free cash flow when compared to the prior year. Our record revenue was distributed across the business as strength was seen both in the U.S.

and international, as well as across our musculoskeletal and enabling technologies portfolios. We continue to lead the market with investments in product development and seek to expand our position as a leader in disruptive technology. I want to thank our global team members for driving operational excellence and focus while continuing to plan and prepare for our pending merger with NuVasive. Operator, we'll now open the call for questions.

Questions & Answers:

Operator

Thank you. [Operator instructions] Our first question comes from Shagun Singh of RBC Capital Markets. Please go ahead.

Unknown speaker

Hi. Congrats on a nice quarter. This is Kendall on for Shagun. I had one quick question about the FTC and the deal closing.

I was wondering if you can give any other commentary about the deal and any other hurdles you might have going forward have the deal closed in Q3. And I also wanted to ask about guidance in the second half of the implied guidance. I was wondering if there's any other room for upside given the business momentum in the second quarter. Thank you so much.

Dan Scavilla -- Executive Vice President, Chief Commercial Officer, President of Trauma

Thanks, Kendall. This is Dan. I'll start with that, and I'll hand it over to Keith. So no, there are no other hurdles related to the upcoming merger, having gone through what we needed with the SEC, obtained what we needed with the shareholders, and now working with and responding to the FTC, we feel like that would be the last step for us to move forward.

We've seen no reason to deviate from our planned third quarter that we stated based on the cadence and the amount of activity back and forth, but we still think that that's a reasonable date for us to look forward to.

Keith Pfeil -- Senior Vice President, Chief Financial Officer

I'll take the second part. Thanks for the question, and thanks for your comments on the quarter. As I think about the new guidance, $1.125 billion, that implies about 5.3% growth in the second half of the year. We feel good about that.

I would say that Globus remains conservative as a company. But when you step back and look at the full year, the full year would put us up 9.99%. We've always said that we seek to be a mid- to high single-digits grower. I think that that puts us at the high end of the range, and we think that the guidance that we're putting out there is appropriate given where we're at.

Operator

Thank you. One moment for our next question. Our next question comes from Matt Miksic of Barclays. Please go ahead.

Matt Miksic -- Barclays -- Analyst

Hi. Thanks for taking the question, and congrats on a really impressive quarter. So I wanted to get an idea as to was this quarter -- did this seem like a surprising quarter to you, the way it played out, the cadence in the quarter? Was it more in line with your expectations? And any color or commentary you can give us? I think a lot of people are trying to figure out are we seeing a bigger summer vacation this year. Are we seeing more seasonal dip in Q3? Just without trying to get a -- quantify a July comment from you is maybe anything you can give us on your sense so far as to what Q3 should shape up to be relative to what was a very strong Q2? And I have one quick follow-up, if I could.

Dan Scavilla -- Executive Vice President, Chief Commercial Officer, President of Trauma

Hey, thanks, Matt. So you know we're always going to give you this answer, right? We're not going to comment on the current quarter just because we're in the process of it. So there's nothing there, we'll disclose with that. I would tell you that Q2, I wouldn't consider a surprise.

I think we had a solid quarter. There was a lot of great activity throughout the months therein throughout the businesses. So whether you look at spine or our enabling technology or trauma, all of those things were well. The international is just solid every single month.

It's really, I think, doing well with the investments we put in this traction. So I would say we were pleased throughout each one of those three months. And like I said, stay tuned for Q3. We'll have to get through those hurdles before we talk about that one.

Operator

Thank you. One moment for our next question. And our next question comes from Matt Blackman of Stifel. Please go ahead.

Emily Christy -- Stifel Financial Corp. -- Analyst

Hi. This is Emily on for Matt. Just was hoping you could talk a little bit about inbound surgeon training volumes, whether on the enabling tech side or the core spine side. And maybe any specific color on uptick in interest from NuVa docs?

Dan Scavilla -- Executive Vice President, Chief Commercial Officer, President of Trauma

Well, thanks for the question, Emily. We have a lot of surge in traffic that occurs throughout the week, usually heavier toward the end of the week. But I would tell you that nothing unusually heavy or lighter than the normal flow in which we do. I think we're pleased with the amount of throughput that we do, whether that be cadaveric training or hands-on with the robot or everything in between.

I'd say it's pretty good that way. With NuVasive itself, there's still a separate entity. And so we haven't done a lot nor can we do a lot with them or their surgeons with planning along those ways. We will expect an uptick when it is approved, and we'll go at that in a heavier pace.

But right now, we're staying within our lane and just focusing on the surgeons that we have.

Emily Christy -- Stifel Financial Corp. -- Analyst

Great. Thank you.

Operator

Thank you. One moment for our next question. And our next question comes from Caitlin Cronin of Canaccord Genuity. Please go ahead.

Caitlin Cronin -- Canaccord Genuity -- Analyst

Hi. This is Caitlin on for Kyle Rose. Congrats on an awesome quarter. Just to touch on this topic, given what others have called out, have you been experiencing any recent supply chain challenges?

Dan Scavilla -- Executive Vice President, Chief Commercial Officer, President of Trauma

Hey, Caitlin, thanks. This is Dan. I would say no, just the opposite. We're very pleased with the strength of our supply chain, both external and internal, whether it be the ability to replenish post-surgery.

We're set building. I would tell you that we're arguably one of our strongest periods, thanks to the hard work of our operations team throughout the world, but in particular here. So I would say we went through Q2, and we're entering Q3 at a point of strength.

Keith Pfeil -- Senior Vice President, Chief Financial Officer

Yes. And the only thing I would add to that is if you count back to last year with some of the supply chain challenges that were called out there in the market, I think we feel better positioned about where we are this year versus last year, and it really ties back to the statements Dan just made.

Caitlin Cronin -- Canaccord Genuity -- Analyst

Awesome. And then just a quick one on the pediatric deformity products you've launched recently. Any plans to launch any other products? How do you really view the attractiveness of this market?

Dan Scavilla -- Executive Vice President, Chief Commercial Officer, President of Trauma

I think if I heard you correctly, first, the two products that I referred to, which are REFLECT and MARVEL, we're very excited about that because it's going to give you a lot of options how to treat those young patients in a way that should hopefully reduce surgeries or further incisions and different items like that in a controlled fashion. So look, this is a market that needs innovation. We're leaning into that innovation. There's no doubt that when the right time comes and the FTC approves this, will bring together a NuVa portfolio and come out with an ever-stronger offering.

These two products, REFLECT and MARVEL, are definitely key for us, and we're really excited to get this pushed into the hands of the surgeons in the U.S.

Operator

Thank you. [Operator instructions] One moment for our next question. And our next question comes from Richard Newitter of Truist Securities. Please go ahead.

Lin Zhang -- Truist Securities -- Analyst

Hi. It's actually Lin on for Rich. So first of all, congrats on the great quarter. So we heard some comments on capital slowdown in the market.

Just wondering if you could [Inaudible] like what you are seeing there?

Keith Pfeil -- Senior Vice President, Chief Financial Officer

This is Keith. Thanks for the question. I think, just to repeat what you said, you asked if there was -- if we were seeing capital slowdowns in the market. I would -- I'll start this.

And Dan, feel free to add. I mean, I think that where we're at today, we're extremely happy with the uptake of our E3D system, as well as our robot. If I look at where we're at today versus last year at this time on a year-to-date basis, I would say that we're ahead and we're happy with where we're at. We're continuing to try to sell more.

But I wouldn't say that we've seen a slowdown in the market, especially when we comp to prior year.

Dan Scavilla -- Executive Vice President, Chief Commercial Officer, President of Trauma

Yes. And I'll just build on that. I think COVID created some disruption in the market, and I think that's carried through the years, not quite solidified and equalized when it comes into the hospitals with what they're struggling with. That said, we're not seeing this year or this quarter any difference, as Keith said.

It's just out there, and we'd all like it to be stronger, but there's nothing noticeable and change for us in Q2 that we would call out as a significant difference.

Lin Zhang -- Truist Securities -- Analyst

That's helpful. Thank you. A follow-up. So on Japan, could you provide us some color like what really drove that strength there?

Dan Scavilla -- Executive Vice President, Chief Commercial Officer, President of Trauma

I'd say the strength in Japan is really the business is really starting to take hold. And as we think about what we've done in the last couple of years, our go-to-market plan of controlling the territories with the reps that we have, that is really taking hold. And really, we're starting to see growth because we saw a period of time where we saw consecutive sales declines. We're not going the other way, and we think that our strategy is starting to take hold.

Lin Zhang -- Truist Securities -- Analyst

Thank you.

Operator

Thank you. One moment for our next question. And our next question comes from Steven Lichtman of Oppenheimer and Company. Please go ahead.

Ron Feiner -- Oppenheimer and Company -- Analyst

Hi, guys. This is Ron on for Steve. Congrats on the great quarter. Wanted to ask if you guys see any signs of salesforce concern or losses because of the pandemic deal.

Are there any initiatives you were putting in place for salesforce retention?

Dan Scavilla -- Executive Vice President, Chief Commercial Officer, President of Trauma

Ron, thanks for the question. No, we have not seen anything right now with our salesforce in Globus and having concerns with that. Really, the best approach that we have is to develop and launch products, get them in their hands, pay them as we do, and look to supply them in a stronger supply chain that way. In doing that and creating that level of innovation and support, we feel like we're one of the best places to be.

I think we have to be mindful of what can happen in the future. Certainly, there is concern with that, and so we're communicating and we're making sure that we interact with our field at a higher rate, just so they're aware of what's going on and where we're going, our commitment to them, and how they will remain vital to us in one of our main growth engines. And so we're really just kind of reminding them of how great they are, making sure that we can provide them with what they need so that we can drive this forward while we're waiting to get the approval and certainly need their hands on and driving as we get through the post-approval.

Keith Pfeil -- Senior Vice President, Chief Financial Officer

And the only thing I'd add to that is, as you look ahead, you're bringing together two companies that are committed to product development, and that's something we see going forward, as well as surgeon education, and you're bringing together two innovators. When it comes to product, I think that should continue to drive excitement across both salesforces.

Ron Feiner -- Oppenheimer and Company -- Analyst

Great. Just a short follow-up. Maybe you guys can give us some commentary about pricing trends in the U.S. in the recent quarter.

Dan Scavilla -- Executive Vice President, Chief Commercial Officer, President of Trauma

Pricing trends really, it's really low single-digit decline. I wouldn't say that that's really any different. As we think about Globus, what we've done to offset price erosion is really launched new products, bring those to the market. We've done that with some of the product launches Dan talked about earlier, as well as things that we have planned for the remainder of this year.

Keith Pfeil -- Senior Vice President, Chief Financial Officer

I would just add, we've seen no significant change in pricing pressures or shifts with that as we look over the past multiple quarters. It's been fairly consistent for us.

Operator

[Operator signoff]

Duration: 0 minutes

Call participants:

Brian Kearns -- Senior Vice President, Business Development and Investor Relations

Dan Scavilla -- Executive Vice President, Chief Commercial Officer, President of Trauma

Keith Pfeil -- Senior Vice President, Chief Financial Officer

Unknown speaker

Matt Miksic -- Barclays -- Analyst

Emily Christy -- Stifel Financial Corp. -- Analyst

Caitlin Cronin -- Canaccord Genuity -- Analyst

Lin Zhang -- Truist Securities -- Analyst

Ron Feiner -- Oppenheimer and Company -- Analyst

More GMED analysis

All earnings call transcripts